Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

API Manufacturing: SOP for Mock Recall Procedure and Execution – V 2.0

Posted on By

API Manufacturing: SOP for Mock Recall Procedure and Execution – V 2.0

Standard Operating Procedure for Mock Recall Procedure and Execution in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/181/2025
Supersedes SOP/API/181/2022
Page No. Page 1 of 15
Issue Date 14/04/2025
Effective Date 16/04/2025
Review Date 14/04/2026

1. Purpose

To outline the procedure for planning, executing, and evaluating mock recalls of Active Pharmaceutical Ingredients (APIs) to verify the robustness of the recall system and ensure compliance with regulatory requirements.

2. Scope

This SOP is applicable to all APIs manufactured and distributed by the company. It includes procedures for initiating a mock recall, tracking product distribution,

documenting actions, evaluating recall efficiency, and reporting outcomes.

3. Responsibilities

  • QA Head: Approves and authorizes the execution of mock recalls and reviews the final report.
  • Recall Coordinator (Designated QA Executive): Plans and executes the mock recall and maintains records.
  • Warehouse/Logistics: Provides distribution data and helps trace batches.
  • Regulatory Affairs: Ensures compliance with regulatory expectations during recall simulation.
  • All Department Heads: Cooperate in providing data and ensuring smooth execution of mock recalls.
See also  API Manufacturing: SOP for System Suitability Testing in HPLC - V 2.0

4. Accountability

The Quality Assurance Department is accountable for the implementation, effectiveness monitoring, and continuous improvement of the recall system.

5. Procedure

5.1 Frequency and Planning

  1. Mock recalls shall be conducted at least once annually or as required by regulatory bodies.
  2. The schedule for mock recall shall be defined in the Annual Quality Plan and approved by QA Head.
  3. The selection of product and batch for mock recall shall be random but should cover a range of APIs over the years.

5.2 Initiation

  1. The Recall Coordinator shall initiate the process using the Mock Recall Initiation Form (Annexure-1), which must include:
    • Selected Product Name
    • Batch Number
    • Manufacture and Expiry Date
    • Reason for Simulation
  2. The QA Head shall approve and authorize the simulation.

5.3 Notification and Team Formation

  1. Constitute a Mock Recall Team including representatives from QA, Warehouse, Production, and Regulatory Affairs.
  2. Issue internal communication to all relevant departments regarding the exercise, ensuring confidentiality and traceability.

5.4 Distribution Traceability

  1. Warehouse/Logistics shall provide the Distribution Log (Annexure-2) showing:
    • Customers or locations where batch was dispatched
    • Date of dispatch
    • Quantity shipped
    • Contact details
  2. The Recall Coordinator shall simulate retrieval of product using this information and document the results in the Mock Recall Execution Sheet (Annexure-3).
See also  API Manufacturing: SOP for Handling of Quarantined Materials - V 2.0

5.5 Reconciliation and Effectiveness

  1. Calculate:
    • Total quantity manufactured
    • Total quantity distributed
    • Quantity available in warehouse
    • Simulated recalled quantity
  2. Evaluate effectiveness based on traceability rate (minimum acceptable: ≥95%).
  3. Record findings in the Mock Recall Evaluation Report (Annexure-4).

5.6 Documentation and Review

  1. QA shall compile all forms, logs, and findings into a single recall file.
  2. The final report shall include:
    • Observations
    • Shortcomings (if any)
    • Corrective actions
  3. QA Head and Site Head shall review and approve the final Mock Recall Summary Report (Annexure-5).

5.7 Corrective Actions and Follow-Up

  1. If deficiencies are found (e.g., untraceable quantity, delayed responses), initiate CAPA using CAPA Form (Annexure-6).
  2. Follow-up must be conducted to ensure all corrective actions are implemented within 30 days.

6. Abbreviations

  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • APQR: Annual Product Quality Review
  • SOP: Standard Operating Procedure

7. Documents

  1. Mock Recall Initiation Form (Annexure-1)
  2. Distribution Log (Annexure-2)
  3. Mock Recall Execution Sheet (Annexure-3)
  4. Mock Recall Evaluation Report (Annexure-4)
  5. Mock Recall Summary Report (Annexure-5)
  6. CAPA Form (Annexure-6)

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211.150 – Distribution Records
  • EU GMP Chapter 8 – Complaints and Product Recall
See also  API Manufacturing: SOP for Cleaning of Manufacturing Equipment - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Mock Recall Initiation Form

Product Batch No. Mfg Date Exp Date Reason
API-X AXP2025 10/02/2025 10/02/2028 Mock Recall – System Evaluation

Annexure-2: Distribution Log

Customer Address Batch No. Qty (kg) Dispatch Date
XYZ Pharma Pune AXP2025 50 15/02/2025

Annexure-3: Mock Recall Execution Sheet

Location Contacted By Date/Time Response Time Qty Traceable
XYZ Pharma Sunita Reddy 12/04/2025 10:00 AM 2 hrs 50 kg

Annexure-4: Mock Recall Evaluation Report

Parameter Target Achieved Remarks
Traceability Rate ≥95% 100% Effective
Response Time ≤4 hrs 2 hrs Compliant

Annexure-5: Mock Recall Summary Report

Recall ID Date Coordinator Outcome Approved By
MR/2025/01 12/04/2025 Rajesh Kumar Successful QA Head

Annexure-6: CAPA Form

CAPA No. Issue Identified Corrective Action Owner Status
CAPA/2025/07 Late response by warehouse Refresher training scheduled Warehouse Head Open

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP New creation QA Head
14/04/2025 2.0 Added CAPA and Summary annexures Audit Feedback QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Cleanroom Pass-Through Equipment Operation – V 2.0
Next Post: Biosimilars: SOP for Aseptic Handling During Inoculation – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version